Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Thromboxane synthetase

HMWK high-molecular-weight kininogen TS thromboxane synthetase... [Pg.159]

Drugs that target other sites of platelet action include thromboxane synthetase inhibitors, serotonin or 5-hydroxytryptamine (5-HT2) receptor blockers, and thromboxane A2 receptor blockers, in addition to cyclooxygenase inhibitors and prostaglandin analogues. [Pg.151]

Banerjee AK, Peters TJ Experimental nonsteroidal anti-inflammatory drug-induced enteropathy in the rat Similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. Gut 1990 3 i 1358— 1364. [Pg.65]

Tokiyoshi K, Ohnishi T, Nii Y. 1991. Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. Surg Neurol 36 112-118. [Pg.90]

Uyama O, Nagatsuka K, Nakabayashi S, Isaka Y, Yoneda S, et al. 1985. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin El alpha in patients with ischemic cerebrovascular disease. Stroke 16 241-244. [Pg.90]

Backon, J. Ginger Inhibition of thromboxane synthetase and stimulation of prostacyclin relevance for medicine and psychiatry. Med Hypotheses 1986 20(3) 271-278. [Pg.546]

Hall and Wolf [217] have proposed a hypothesis, concerning the pathogenesis of post-traumatic central nervous system ischaemia, which integrates an injury-induced rise in intracellular Ca2+, the increased synthesis of vasoactive prostanoids and progressive microvascular lipid peroxidation. The model used anaesthetised cats with a contusion injury to the lumbar spinal cord. Antioxidants, vitamin E and selenium, were compared with various Ca2 + antagonists, cyclo-oxygenase inhibitors, a thromboxane synthetase inhibitor and the stable prostacyclin analogue. The most impressive preservation of post-traumatic spinal cord blood flow was provided by the antioxidants. [Pg.274]

Figure 16.24 Major prostaglandin and leukotriene products derived from arachidonic acid via the cyclooxygenase and 5-lipooxygenase pathways. Major enzymes 1, cyclooxygenase 2, hydroperoxidase 1 + 2, prostaglandin endoperoxidase synthetase 3, thromboxane synthetase 4, prostacyclin synthetase 5, 5-lipooxygenase 6, 9-ketoisomerase 7, PGH-PGF2a reductase 8, 11-ketoisomerase 9, PGE reductase 10, PGD reductase. (Reproduced by permission from Nelson NA, Kelly RC, Johnson, RA. Prostaglandins and the arachidonic acid cascade. Chem Eng News August 30-44, 1982.)... Figure 16.24 Major prostaglandin and leukotriene products derived from arachidonic acid via the cyclooxygenase and 5-lipooxygenase pathways. Major enzymes 1, cyclooxygenase 2, hydroperoxidase 1 + 2, prostaglandin endoperoxidase synthetase 3, thromboxane synthetase 4, prostacyclin synthetase 5, 5-lipooxygenase 6, 9-ketoisomerase 7, PGH-PGF2a reductase 8, 11-ketoisomerase 9, PGE reductase 10, PGD reductase. (Reproduced by permission from Nelson NA, Kelly RC, Johnson, RA. Prostaglandins and the arachidonic acid cascade. Chem Eng News August 30-44, 1982.)...
Apprill P, Schmitz JM, Campbell WB et al. (1985) Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and a-adrenergic receptors. Circulation 72 397-405... [Pg.281]

Shebuski RJ, Storer BL, Fujita T (1988) Effect of thromboxane synthetase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res 52 381-392 Yasuda T, Gold HK, Fallon JT et al. (1988) Monoclonal antibody against the platelet glycoprotein (GP) Ilb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue type plasminogen activator. J Clin Invest 81 1284-1291... [Pg.287]

Kyowa Hakko Kogyo Co.) anti-inflammatory thromboxane synthetase inhibitor "discovery ... [Pg.26]

Mestel F, Oetliker O, Bede E, et al. Severe bleeding assodated with defective thromboxane synthetase [letter]. Lancet 1980 1 157. [Pg.438]

Grieve EM, Hawksworth GM, Simpson JG, Whiting PH. Effect of thromboxane synthetase inhibition and angiotensin converting enzyme inhibition on acute cyclosporin A nephrotoxicity. Biochem Pharmacol 1990 40 2323-2329. [Pg.652]

Grieve EM, Hawksworth GM, 5impson JG, Whiting PH.The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition. Biochem Pharmacol 1993 45 1351-1354. [Pg.655]

Gladue RP, Newborg MF. The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats.Transplantation 1991 52 837-841. [Pg.655]

The two proposed mechanisms by which nitrates promote venodilatation are stimulation of cyclic guanosine monophosphate (GMP) production and inhibition of thromboxane synthetase. [Pg.16]

Moore J N, Hardee M M, HanJee G E 1986 Modulation of arachidonic acid metabolism in endotoxic horses comparison of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor. American Journal of Veterinary Research 47 110-113... [Pg.265]

See other pages where Thromboxane synthetase is mentioned: [Pg.54]    [Pg.1543]    [Pg.137]    [Pg.136]    [Pg.179]    [Pg.578]    [Pg.345]    [Pg.238]    [Pg.540]    [Pg.542]    [Pg.523]    [Pg.256]    [Pg.261]    [Pg.45]    [Pg.1543]    [Pg.396]    [Pg.431]    [Pg.432]    [Pg.301]    [Pg.179]    [Pg.73]    [Pg.6]    [Pg.10]    [Pg.11]    [Pg.426]    [Pg.527]    [Pg.655]    [Pg.264]    [Pg.829]    [Pg.91]   
See also in sourсe #XX -- [ Pg.28 ]

See also in sourсe #XX -- [ Pg.522 ]

See also in sourсe #XX -- [ Pg.79 ]



SEARCH



Prostaglandins thromboxane synthetase

Thromboxan

Thromboxane Thromboxanes

Thromboxane synthetase inhibitors

Thromboxane synthetase receptor

Thromboxane synthetase receptor antagonists

Thromboxane synthetase, inhibition

Thromboxanes

© 2024 chempedia.info